Detalhe da pesquisa
1.
Daratumumab in Indian patients with relapsed and refractory multiple myeloma: a prospective, multicenter, phase IV study.
Future Oncol
; 20(4): 191-205, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-38116642
2.
Paclitaxel injection concentrate for nanodispersion versus nab-paclitaxel in women with metastatic breast cancer: a multicenter, randomized, comparative phase II/III study.
Breast Cancer Res Treat
; 156(1): 125-34, 2016 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-26941199
3.
Cancer Trials Ecosystem in India-Ready for Prime Time?
JCO Glob Oncol
; 10: e2300405, 2024 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-38870438
4.
A Phase IIIb Open-Label, Single-Arm Study of Afatinib in EGFR TKI-Naïve Patients with EGFRm+ NSCLC: Final Analysis, with a Focus on Patients Enrolled at Sites in China.
Target Oncol
; 17(1): 1-13, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35020119
5.
Fixed dose combination of capecitabine and cyclophosphamide in metastatic breast cancer: Results from THE ENCLOSE phase 2/3 randomized multicenter study.
Breast
; 60: 147-154, 2021 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-34624757
6.
Practical Consensus Recommendations for Optimizing Risk versus Benefit of Chemotherapy in Patients with HR Positive Her2 Negative Early Breast Cancer in India.
South Asian J Cancer
; 10(4): 213-219, 2021 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-34984198
7.
Patterns of epidermal growth factor receptor testing across 111 tertiary care centers in India: Result of a questionnaire-based survey.
South Asian J Cancer
; 7(3): 203-206, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-30112342
8.
Management of Lymphomas: Consensus Document 2018 by an Indian Expert Group.
Indian J Hematol Blood Transfus
; 34(3): 398-421, 2018 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-30127547
9.
Randomized study of etirinotecan pegol versus irinotecan as second-line treatment for metastatic colorectal cancer.
Cancer Chemother Pharmacol
; 80(6): 1161-1169, 2017 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-29043412
10.
Efficacy of erlotinib as first-line maintenance therapy in patients with locally advanced or metastatic nonsmall cell lung cancer who have not experienced disease progression or unacceptable toxicity during chemotherapy.
South Asian J Cancer
; 6(1): 1-5, 2017.
Artigo
em Inglês
| MEDLINE | ID: mdl-28413785
11.
A double-blind, randomised, placebo-controlled, phase 2b study evaluating sorafenib in combination with paclitaxel as a first-line therapy in patients with HER2-negative advanced breast cancer.
Eur J Cancer
; 49(2): 312-22, 2013 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-22954665